DNA定序市场－全球产业规模、份额、趋势、机会及预测（按产品类型、技术、应用、最终用户、地区和竞争格局划分，2021-2031年）

全球DNA定序市场预计将从2025年的155.6亿美元成长到2031年的471.4亿美元，复合年增长率为20.29%。

DNA定序是指利用先进的设备、耗材和生物资讯服务，对DNA分子内核苷酸碱基序列进行精确识别，从而解码遗传讯息。市场成长的主要驱动力是定序成本的持续下降以及临床上对个人化医疗日益增长的需求，尤其是在肿瘤学和罕见疾病诊断领域。这些核心驱动因素不同于昙花一现的技术趋势，并得益于基因组数据产生的庞大规模。例如，全球基因组与健康联盟（Global Alliance for Genomics and Health）报告称，到2024年，其合作伙伴网络将管理超过300万个基因组，这表明目前在研究和临床环境中利用的遗传物质数量巨大。

然而，复杂的监管环境，特别是检查室自建检测（LDT）的监管，是限制市场扩张的一大障碍。这些诊断检测的合规性和核准流程日益增长的不确定性，阻碍了其商业化进程，并可能延缓定序技术在临床环境中的快速应用，儘管市场需求不断增长。

市场驱动因素

次世代定序平台技术的快速发展正在改变市场格局，降低了进入门槛，并促进了高通量分析。这一发展动能体现在新型台式定序仪的涌现和改进的化学方法上，这些方法降低了每千兆碱基的成本，有效地推动了基因组分析能力向大型基因组中心以外的分散化。对这些创新技术的大量投资凸显了它们在市场扩张中的关键作用。例如，Element Biosciences在2024年7月的D轮资金筹措公告中宣布，已筹集2.77亿美元，用于加速其AVITI桌上型定序仪的商业化。这些进步创造了竞争格局，迫使现有企业进行创新，并透过提高数据品质和降低成本使用户受益。 Illumina公司2024年第三季的核心营收达到11亿美元，显示全球对定序基础设施的依赖程度依然很高，也反映了这个高科技产业的规模。

精准医疗和药物基因体学的加速应用是推动市场成长的第二大主要因素，尤其是在肿瘤学领域。随着定序日益融入临床常规，对液态生物检体和微量残存疾病（MRD）监测的需求激增，从而实现了非侵入性肿瘤分析和个人化治疗策略。癌症患者诊断检测量的激增也推动了这项转变。例如，Natera公司在2024年11月发布的2024年第三季财报中报告称，其处理了约137,100例癌症检测，较去年同期增长54%。这种快速应用表明，临床医生越来越依赖基因组数据来制定治疗决策，而定序也从研究工具转变为复杂疾病管理的关键标准。

市场挑战

全球DNA定序市场面临的主要障碍之一是实验室自建检测（LDT）监管架构日益复杂。这种日益严格的审查造成了不确定性，迫使临床检查室将大量资源从创新转移到合规性。随着监管机构寻求将这些检测重新归类​​为医疗设备，上市前审查和品质系统标准相关的预期成本和行政负担构成了进入障碍。因此，实验室不愿投资新型定序技术或扩展其检测项目，直接阻碍了先进基因组学应用的商业性化推广。

监管瓶颈限制了市场成长，尤其是在细分诊断领域，迫使服务提供者缩减服务规模。遵守严格的核准通讯协定带来的财务负担往往超过了用于检测罕见疾病的低通量检测的获利潜力。根据诊断和实验室医学协会 (ADLM) 2024 年的一项调查，超过 50% 的临床检查室正在考虑停止某些实验室自建检测项目，原因是 FDA 新监管规则带来的营运和财务负担。诊断选择的减少限制了患者获得基于定序的疗法的机会，导致对定序设备和耗材的整体需求下降。

市场趋势

第三代长读长定序技术的兴起正在改变市场格局，它能够分析短读长定序平台难以处理的复杂基因组区域。这些系统可以即时读取生物DNA分子，并准确地识别结构变异和表观遗传修饰，且不存在扩增偏差。这项优势正推动其在临床研究和应用市场中的广泛应用，因为在这些领域，完整的基因组可视性对于研究大规模遗传变异至关重要。例如，牛津奈米孔技术公司在其2025年3月发布的「截至2024年12月31日止年度财务业绩」中报告称，由于其平台应用范围的扩大，公司收入达到1.832亿英镑（不计外汇波动影响，增长11.1%）。

同时，将人工智慧 (AI) 和机器学习 (ML) 整合到基因组分析中，对于解读现代定序仪产生的大量数据至关重要。随着主要瓶颈从数据生成转向数据分析，人工智慧模型正被用于加速变异检测和功能预测。这些演算法使研究人员能够更快地检测到致病突变，从而显着提升基因组数据在精准医疗中的价值。为了体现这一趋势，10x Genomics 在其于 2025 年 2 月发布的“2024 年第四季度及全年财务业绩”中宣布启动“十亿细胞项目”，旨在构建一个包含十亿个细胞的数据集，以推动人工智能模型开发的快速发展。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球DNA定序市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品类型（设备、耗材、服务）
  • 依技术分类（桑格定序、次世代定序(NGS)、第三代定序、其他）
  • 按应用领域（诊断、调查、个人化医疗、刑事鑑定等）
  • 按最终用户（医院/医疗机构、学术研究机构、製药/生技公司、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美DNA定序市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲DNA定序市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区DNA定序市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲DNA定序市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美DNA定序市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球DNA定序市场：SWOT分析

第十四章 波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Thermo Fisher Scientific Inc.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd.
• Illumina, Inc.
• QIAGEN NV
• Merck KGaA
• Macrogen, Inc.
• PerkinElmer, Inc.
• Eurofins Scientific Limited

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global DNA Sequencing Market is projected to expand from USD 15.56 Billion in 2025 to USD 47.14 Billion by 2031, registering a CAGR of 20.29%. DNA sequencing is characterized as the exact identification of the nucleotide base order within a DNA molecule, achieved through advanced instrumentation, consumables, and bioinformatics services that decode genetic data. The market's upward trajectory is chiefly driven by the continuous decline in sequencing costs and the rising clinical requirement for personalized medicine, specifically within oncology and rare disease diagnostics. These core drivers differ from temporary technological trends and are bolstered by the immense scale of genomic data production; for instance, the Global Alliance for Genomics and Health reported that in 2024, their partner network managed over 3,000,000 genomes, demonstrating the significant volume of genetic material currently employed in research and clinical settings.

However, a major obstacle limiting wider market growth is the increasingly intricate regulatory landscape, particularly regarding the supervision of Laboratory Developed Tests (LDTs). The escalating uncertainty regarding compliance and approval processes for these diagnostic assays forms a commercialization bottleneck, which could potentially delay the swift integration of sequencing technologies into clinical environments despite rising demand.

Market Driver

Swift technological progress in Next-Generation Sequencing Platforms is transforming the market structure by reducing entry barriers and facilitating high-throughput analysis. This momentum is defined by the arrival of new benchtop sequencers and chemistry upgrades that lower the cost per gigabase, effectively decentralizing genomic capabilities beyond large-scale genome centers. The significant investment in these disruptive technologies highlights their essential role in market expansion; for example, Element Biosciences announced in its 'Series D Funding Announcement' in July 2024 that it raised $277 million to hasten the commercial launch of its AVITI benchtop sequencer. Such developments create a competitive landscape that forces incumbent companies to innovate, benefiting users through enhanced data quality and lower costs. To demonstrate the scale of this high-tech sector, Illumina reported third-quarter core revenue of $1.1 billion in 2024, indicating continued global dependence on sequencing infrastructure.

The hastened adoption of Precision Medicine and Pharmacogenomics acts as the second major catalyst for market growth, especially within oncology. As sequencing becomes embedded in clinical routines, there is a surge in demand for liquid biopsy and minimal residual disease (MRD) monitoring, enabling non-invasive tumor profiling and tailored treatment strategies. This shift is substantiated by the rapidly increasing volume of diagnostic tests for cancer patients. For instance, Natera reported in its 'Third Quarter 2024 Financial Results' in November 2024 that it processed roughly 137,100 oncology tests, a 54% rise over the same period the previous year. This swift adoption illustrates how clinicians increasingly depend on genomic data for therapeutic decisions, transforming sequencing from a research instrument into a critical standard of care for managing complex conditions.

Market Challenge

The central obstacle hindering the Global DNA Sequencing Market is the progressively complex regulatory framework governing Laboratory Developed Tests (LDTs). This intensified scrutiny generates uncertainty, compelling clinical laboratories to redirect essential resources from innovation toward compliance efforts. As regulators aim to reclassify these assays as medical devices, the projected costs and administrative workloads linked to premarket reviews and quality system standards become exclusionary. Consequently, laboratories are less inclined to invest in novel sequencing technologies or broaden their testing menus, which directly suppresses the commercial uptake of advanced genomic applications.

This regulatory bottleneck curbs market growth by forcing service providers to reduce their offerings, specifically for niche diagnostics. The financial burden of adhering to strict approval protocols often exceeds the revenue potential of low-volume tests employed in rare disease detection. According to a 2024 survey by the Association for Diagnostics and Laboratory Medicine, over 50% of clinical laboratories intended to stop offering certain laboratory-developed tests due to the operational and financial strains resulting from the new FDA oversight rule. This decrease in available diagnostic options restricts patient access to sequencing-based treatments, thereby lowering the total demand for sequencing instruments and consumables.

Market Trends

The rise of Third-Generation Long-Read Sequencing Technologies is transforming the market by addressing complex genomic regions that short-read platforms struggle to analyze. These systems read native DNA molecules in real-time, allowing for the accurate identification of structural variants and epigenetic modifications without the bias caused by amplification. This ability is fueling growing adoption in clinical research and applied markets, where complete genomic visibility is essential for studying large-scale genetic variation. For example, Oxford Nanopore Technologies reported in its 'Annual results for the year ended 31 December 2024' released in March 2025 that revenue reached £183.2 million, an 11.1% increase on a constant currency basis, attributed to the wider use of its platform.

Concurrently, the integration of Artificial Intelligence and Machine Learning for Genomic Analysis is proving indispensable for interpreting the massive amounts of data produced by modern sequencers. As the primary bottleneck shifts from data generation to analysis, AI-powered models are being utilized to speed up variant calling and functional prediction. These algorithms enable researchers to detect disease-causing mutations more rapidly, greatly enhancing the value of genomic data for precision medicine. Highlighting this trend, 10x Genomics announced in its 'Fourth Quarter and Full Year 2024 Financial Results' in February 2025 the initiation of the Billion Cells Project, aiming to create a one billion cell dataset specifically to drive rapid advancements in AI model development.

Key Market Players

• Thermo Fisher Scientific Inc.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd.
• Illumina, Inc.
• QIAGEN N.V.
• Merck KGaA
• Macrogen, Inc.
• PerkinElmer, Inc.
• Eurofins Scientific Limited

Report Scope

In this report, the Global DNA Sequencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

DNA Sequencing Market, By Product Type

• Instruments
• Consumables
• Services

DNA Sequencing Market, By Technology

• Sanger Sequencing
• Next-Generation Sequencing (NGS)
• Third-Generation Sequencing
• Others

DNA Sequencing Market, By Application

• Diagnostics
• Research
• Personalized Medicine
• Forensic Testing
• Others

DNA Sequencing Market, By End User

• Hospitals and Healthcare Organizations
• Academics and Research Institutions
• Pharmaceutical and Biotechnology Companies
• Others

DNA Sequencing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global DNA Sequencing Market.

Available Customizations:

Global DNA Sequencing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global DNA Sequencing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Instruments, Consumables, Services)
  • 5.2.2. By Technology (Sanger Sequencing, Next-Generation Sequencing (NGS), Third-Generation Sequencing, Others)
  • 5.2.3. By Application (Diagnostics, Research, Personalized Medicine, Forensic Testing, Others)
  • 5.2.4. By End User (Hospitals and Healthcare Organizations, Academics and Research Institutions, Pharmaceutical and Biotechnology Companies, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America DNA Sequencing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Technology
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States DNA Sequencing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada DNA Sequencing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico DNA Sequencing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe DNA Sequencing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany DNA Sequencing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. France DNA Sequencing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom DNA Sequencing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy DNA Sequencing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain DNA Sequencing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia Pacific DNA Sequencing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China DNA Sequencing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India DNA Sequencing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan DNA Sequencing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea DNA Sequencing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia DNA Sequencing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. Middle East & Africa DNA Sequencing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia DNA Sequencing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE DNA Sequencing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa DNA Sequencing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. South America DNA Sequencing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil DNA Sequencing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia DNA Sequencing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina DNA Sequencing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global DNA Sequencing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Agilent Technologies, Inc.
• 15.3. Bio-Rad Laboratories, Inc.
• 15.4. F. Hoffmann-La Roche Ltd.
• 15.5. Illumina, Inc.
• 15.6. QIAGEN N.V.
• 15.7. Merck KGaA
• 15.8. Macrogen, Inc.
• 15.9. PerkinElmer, Inc.
• 15.10. Eurofins Scientific Limited

16. Strategic Recommendations

17. About Us & Disclaimer